Blindingly obvious (once revealed): a novel approach to blinding medicinal products for injection

@inproceedings{Sanders2015BlindinglyO,
  title={Blindingly obvious (once revealed): a novel approach to blinding medicinal products for injection},
  author={Julia Sanders and J Townson and Nadine Aawar},
  year={2015}
}
Background Blinding is a pre-requisite to high standard clinical trials of medicinal products (CTIMPs), but this requirement, can on occasions, present complex challenges in placebo matching and delivery. OBS2 is a trial evaluating the effectiveness of early fibrinogen administration in the management of complex postpartum haemorrhage. Fibrinogen… CONTINUE READING